Canada markets open in 5 hours 57 minutes

InspireMD, Inc. (NSPR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.0300-0.0400 (-1.93%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.0700
Open1.9800
Bid0.0000 x 900
Ask0.0000 x 1400
Day's Range1.9800 - 2.0700
52 Week Range1.8000 - 6.8200
Volume1,657
Avg. Volume17,459
Market Cap16.896M
Beta (5Y Monthly)1.41
PE Ratio (TTM)N/A
EPS (TTM)-2.0800
Earnings DateAug 08, 2022 - Aug 12, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.25
  • GlobeNewswire

    InspireMD Provides Highlights from Recent Presentations and Live Case Transmission at LINC 2022

    Successful live case transmission again demonstrated CGuard’s™ differentiated patient protection features and ease of useTEL AVIV, Israel, June 09, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today provided the following highlights from multiple presentations and live case transmission, all featuring its CGuard™ Embolic Prevention Stent System, from LINC 2022, which was held June 6-9. “Our partici

  • GlobeNewswire

    InspireMD’s CGuard™ Embolic Prevention Stent System to be Featured in Clinical Presentations and a Live Case Transmission at LINC 2022

    Live case transmission designed to demonstrate ease-of-use and exceptional patient safety features of CGuard™ Embolic Prevention System (EPS)TEL AVIV, Israel, June 02, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced that the company will participate in the Leipzig Interventional Course (LINC) 2022, which is being held June 6-9 in Leipzig, Germany. The company will occupy Booth #36 duri

  • GlobeNewswire

    InspireMD Reports First Quarter 2022 Financial Results and Business Update

    - 20% growth in CGuard™ revenue Year-over-Year - - C-Guardian FDA IDE Trial Completes First European Enrollment - - Held Key Opinion Leader (KOL) Webinar on Carotid Artery Disease Management and Stroke Prevention, highlighting CGuard™ clinical advantages - - European logistics hub established with BOMI Group –for direct market access as well as establishing the commercial footprint for a growing portfolio of new systems across different channels – - Upcoming Clinical Evidence and Live Case to be